Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone in primary hyperparathyroidism
ISRCTN33941607Phase 3Completed
- Sponsor
- Medical University of Graz
- Start
- Jul 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eplerenone in primary hyperparathyroidism (PHPT), sponsored by Medical University of Graz. Primary endpoint: Mean change of iPTH(1-84) levels. Started Jul 2012; status: completed.
02
Drugs
eplerenone
03
Conditions
primary hyperparathyroidism (PHPT)
Beyond the preview
Go deeper on ISRCTN33941607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN33941607.